Identifying the Neural Basis of Capability for Suicide

Unity Health Toronto

Status

Active, not recruiting

Conditions

Major Depressive Disorder

Suicidal Ideation

Suicide

Psychiatric Illness

Treatments

Procedure: fMRI

Study type

Observational

Funder types

Other

Identifiers

NCT03327129

SRO-01

Details and patient eligibility

About

Since capability for suicide involves overriding potential pain, and the opioid system plays a strong role in controlling pain perception, it follows that capability for suicide may be impacted by the opioid system. The goal of the proposed research is to identify the neural network underlying capability for suicide in order to determine if it can be a target for identifying high-risk individuals and for intervention.

Full description

Little evidence exists distinguishing individuals with suicidal ideation (SI) from those at risk for suicidal behaviour, illustrating the need for more comprehensive biomarkers for clinicians to guide their treatment approach and for new treatment avenues. Current theories of suicide have suggested the importance of an individual's capability for suicide in predicting suicide attempt or death. Building on this, Yovell and colleagues (2016) provided important preliminary data that the opioid system affects suicide risk, but the neural mechanisms and their relationship to capability for suicide are unclear. The goal of the proposed research is to identify the neural network underlying capability for suicide using functional magnetic resonance imaging (fMRI) in order to determine if it can be a target for identifying high-risk individuals and for intervention.

Enrollment

90 estimated patients

Sex

All

Ages

18 to 70 years old

Volunteers

Accepts Healthy Volunteers

Inclusion and exclusion criteria

Inclusion criteria for patients:

Age between 18-70
Capability of giving informed consent
Not currently pregnant or lactating (due to potential confounding of brain activity as a result of differing hormone levels)

Exclusion criteria for patients:

Lifetime history of any substance abuse, psychosis
Current use of any opioid acting drugs
Current use of any prescription pain medication
Use of over the counter pain medications within 15 hours of brain scan
For daily users of a benzodiazepine, stimulant or atypical antipsychotic, dose within 12 hours of brain scan
For as needed users of a benzodiazepine, stimulant or atypical antipsychotic, dose within 2 weeks of brain scan. This is because non-daily use will have more unpredictable effects on brain imaging results than those who are using these medications on a regular basis. The 2 weeks will ensure the drug is not in the system.
Medical condition requiring immediate investigation or treatment
Participation in experimental treatment trials for the study duration.

Healthy control inclusion criteria: Ages between 18 and 70 years, capable of giving informed consent, not pregnant or lactating, no lifetime history of Axis I/II disorders, no history of antidepressant or mood stabilizer use, no treatment for acute or ongoing medical condition, no use of any over the counter pain medication for at least 15 hours prior to the brain scan.